يعرض 1 - 20 نتائج من 802 نتيجة بحث عن '(( significantly increased decrease ) OR ( significant ((anti decrease) OR (a decrease)) ))~', وقت الاستعلام: 0.50s تنقيح النتائج
  1. 1
  2. 2
  3. 3

    Inotodiol decreases clone formation in HCC cells. حسب Yushuang Xing (20636685)

    منشور في 2025
    "…In addition, inotodiol showed to induce apoptosis, characterized by an increase in Bax expression, a decrease in Bcl-2, Bcl-XL and MCL1 expression, the initiation of cleaved PARP1 and cleaved caspase 3, and inhibition of the MAPK/ERK pathway. …"
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15

    Presentation 1_Prehospital tranexamic acid decreases early mortality in trauma patients: a systematic review and meta-analysis.pdf حسب Yi Li (1144)

    منشور في 2025
    "…</p>Conclusion<p>Prehospital TXA decreases early (24-h) mortality in trauma patients without a significant increase in the risk of VTE and other complications, and further studies are still needed to improve and optimize its management strategy.…"
  16. 16

    Data Sheet 1_Prehospital tranexamic acid decreases early mortality in trauma patients: a systematic review and meta-analysis.docx حسب Yi Li (1144)

    منشور في 2025
    "…</p>Conclusion<p>Prehospital TXA decreases early (24-h) mortality in trauma patients without a significant increase in the risk of VTE and other complications, and further studies are still needed to improve and optimize its management strategy.…"
  17. 17
  18. 18

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  19. 19

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  20. 20

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"